参考文献/References:
[1] Roth GA,Johnson C,Abajobir A,et al. Global,regional,and national burden of cardiovascular diseases for 10 causes,1990 to 2015[J]. J Am Coll Cardiol,2017,70(1):1-25.
[2] 《中国心血管健康与疾病报告2020》编写组. 《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究,2021,19(7):582-590.
[3] Brousseau ME,Millar JS,Diffenderfer MR,et al. Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-Ⅱ-containing HDL subspecies and apolipoprotein A-Ⅱmetabolism[J]. J Lipid Res,2009,50(7):1456-1462.
[4] Khalaf RA,Awad M,AL-Qirim T,et al. Synthesis and molecular modeling of novel 3,5-bis(trifluoromethyl) benzylamino benzamides as potential CETP inhibitors[J]. Med Chem,2022,18(4):417-426.
[5] Rye KA,Bursill CA,Lambert G,et al. The metabolism and anti-atherogenic properties of HDL[J]. J Lipid Res,2009,50(suppl):S195-S200.
[6] Banerjee S,De A. Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases:an update[J]. Drug Discov Today,2021,26(7):1759-1764.
[7] Mohammadpour AH,Akhlaghi F. Future of cholesteryl ester transfer protein(CETP) inhibitors:a pharmacological perspective[J]. Clin Pharmacokinet,2013,52(8):615-626.
[8] Armitage J,Holmes MV,Preiss D. Cholesteryl ester transfer protein inhibition for preventing cardiovascular events:JACC review topic of the week[J]. J Am Coll Cardiol,2019,73(4):477-487.
[9] Barter PJ,Caulfield M,Eriksson M,et al. Effects of torcetrapib in patients at high risk for coronary events[J]. N Engl J Med,2007,357(21):2109-2122.
[10] Williams SA,Murthy AC,Delisle RK,et al. Improving assessment of drug safety through proteomics:early detection and mechanistic characterization of the unforeseen harmful effects of torcetrapib[J]. Circulation,2018,137(10):999-1010.
[11] Schwartz GG,Olsson AG,Abt M,et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome[J]. N Engl J Med,2012,367(22):2089-2099.
[12] Rhainds D,Packard CJ,Brodeur MR,et al. Role of adenylate cyclase 9 in the pharmacogenomic response to dalcetrapib:clinical paradigm and molecular mechanisms in precision cardiovascular medicine[J]. Circ Genom Precis Med,2021,14(2):e003219.
[13] Tardif JC,Dubé MP,Pfeffer MA,et al. Study design of Dal-GenE,a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib[J]. Am Heart J,2020,222 :157-165.
[14] Schwartz GG,Leiter LA,Ballantyne CM,et al. Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease[J]. Diabetes Care,2020,43(5):1077-1084.
[15] Eyvazian VA,Frishman WH. Evacetrapib:another CETP inhibitor for dyslipidemia with no clinical benefit[J]. Cardiol Rev,2017,25(2):43-52.
[16] Nicholls SJ,Ray KK,Ballantyne CM,et al. Comparative effects of cholesteryl ester transfer protein inhibition,statin or ezetimibe on lipid factors:the ACCENTUATE trial[J]. Atherosclerosis,2017,261:12-18.
[17] Lincoff AM,Nicholls SJ,Riesmeyer JS,et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease[J]. N Eng J Med,2017,376(20):1933-1942.
[18] Menon V,Kumar A,Patel DR,et al. Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial[J]. BMJ Open Diabetes Res Care,2020,8(1):e000943.
[19] Bahbah EI,Shehata MSA,Alnahrawi SI,et al. Safety and efficacy of evacetrapib in patients with inadequately-controlled hypercholesterolemia and high cardiovascular risk;a meta-analysis of randomized placebo-controlled trials[J]. Prostaglandins Leukot Essent Fatty Acids,2021,168:102282.
[20] Gotto AM Jr ,Kher U,Chatterjee MS,et al. Lipids,safety parameters,and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study[J]. J Cardiovasc Pharmacol Ther,2014,19(6):543-549.
[21] Brinton EA,Kher U,Shah S,et al. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE(Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial[J]. J Clin Lipidol,2015,9(1):65-71.
[22] HPS3/TIMI55–REVEAL Collaborative Group,Bowman L,Hopewell JC,et al. Effects of anacetrapib in patients with atherosclerotic vascular disease[J]. N Engl J Med,2017,377(13):1217-1227.
[23] Thomas T,Zhou H,Karmally W,et al. CETP(cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects[J]. Arterioscler Thromb Vasc Biol,2017,37(9):1770-1775.
[24] HPS3/TIMI55-REVEAL Collaborative Group,Writing Committee,Sammons E,et al. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease[J]. Eur Heart J,2022,43(14):1416-1424.
[25] Vachal P,Duffy JL,Campeau LC,et al. Invention of MK-8262,a cholesteryl ester transfer protein(CETP) inhibitor backup to anacetrapib with best-in-class properties[J]. J Med Chem,2021,64(18):13215-13258.
[26] Wilson DP,Jacobson TA,Jones PH,et al. Use of lipoprotein(a) in clinical practice:a biomarker whose time has come. A scientific statement from the National Lipid Association[J]. J Clin Lipidol,2019,13(3):374-392.
[27] Ford J,Lawson M,Fowler D,et al. Tolerability,pharmacokinetics and pharmacodynamics of TA-8995,a selective cholesteryl ester transfer protein(CETP) inhibitor,in healthy subjects[J]. Br J Clin Pharmacol,2014,78(3):498-508.
[28] Hovingh GK,Kastelein JJP,van Deventer SJH,et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia(TULIP):a randomised,double-blind,placebo-controlled phase 2 trial[J]. Lancet,2015,386(9992):452-460.
[29] Kim CO,Oh ES,Choi C,et al. Pharmacokinetics,pharmacodynamics and safety of CKD-519,a CETP inhibitor,in healthy subjects[J]. Drug Des Devel Ther,2016,10:3763-3770.
[30] Kim CO,Jeon S,Han S,et al. A population pharmacokinetic and pharmacodynamic model of CKD-519[J]. Pharmaceutics,2020,12(6):373.
[31] Dasari MR,Bapat A,Vittal S,et al. Safety,tolerability,pharmacokinetic and pharmacodynamic profile of multiple-doses of DRL-17822,a potent cholesteryl ester transfer protein inhibitor in healthy male subjects[J]. Circulation,2010,122:A13981.
[32] Kruithof AC,Kumar R,Stevens J,et al. Effect of food on the pharmacokinetics of 2 formulations of DRL-17822,a novel selective cholesteryl ester transfer protein(CETP) inhibitor,in healthy males[J]. Clin Pharmacol Drug Dev,2019,8(8):1042-1052.
[33] Goulooze SC,Kruithof AC,Alikunju S,et al. The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteers[J]. Br J Clin Pharmacol,2020,86(10):2095- 2101.
[34] Tall AR,Rader DJ. Trials and tribulations of CETP inhibitors[J]. Circ Res,2018,122(1):106-112.
[35] Furtado JD,Ruotolo G,Nicholls SJ,et al. Pharmacological inhibition of CETP(cholesteryl ester transfer protein) increases HDL(high-density lipoprotein) that contains ApoC3 and other HDL subspecies associated with higher risk of coronary heart disease[J]. Arterioscler Thromb Vasc Biol,2022,42(2):227-237.
[36] Su X,Li GY,Deng YJ,et al. Cholesteryl ester transfer protein inhibitors in precision medicine [J]. Clin Chim Acta,2020,510:733-740.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(7):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(7):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[4]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(7):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(7):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(7):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[7]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(7):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[8]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(7):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
[9]欧阳运峰 李皇庆 李璐 阳军.脂蛋白a：动脉粥样硬化性心血管疾病防治新靶点[J].心血管病学进展,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
OUYANG Yunfeng,LI Huangqing,LI Lu,et al.Lipoprotein A:a New Target for Prevention and Treatment of Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(7):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
[10]安海英 涂建成.载脂蛋白B与非高密度脂蛋白胆固醇在ASCVD防控中的应用价值[J].心血管病学进展,2022,(9):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]
AN Haiying,TU Jiancheng.Application Value of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol in ASCVD Prevention and Control[J].Advances in Cardiovascular Diseases,2022,(7):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]